Cochrane Review Finds Weak Evidence for Medical Cannabis in Insomnia

Nine Clinical Trials Evaluated Regulated Cannabis for Sleep

Researchers analyzed nine clinical trials to determine whether medical cannabis relieves chronic sleep problems. The review, published by Cochrane, pooled data from 537 adults between 18 and 76 years of age who sought care for insomnia. Most participants had primary insomnia, which means their sleeplessness was not caused by a separate underlying medical condition.

Investigators evaluated regulated medical cannabis formulations rather than recreational products. These products contained measured amounts of tetrahydrocannabinol (THC) and cannabidiol (CBD) delivered through oral tablets, sprays, or oils. Eight of the nine studies compared medical cannabis directly against an inactive placebo, while one study compared it to amitriptyline, an antidepressant drug sometimes prescribed for sleep disruption.

Sleep Quality and Total Rest Showed Negligible Measurable Changes

Across the placebo-controlled studies, medical cannabis produced little or no clinically meaningful improvement in sleep quality or total hours slept. Participants receiving cannabis reported similar sleep satisfaction compared to participants receiving a placebo. The preparations also failed to demonstrate consistent improvements in daytime functioning.

The researchers identified common side effects among participants who received active cannabis treatments. Those using medical cannabis reported higher rates of mild adverse events, specifically dizziness and dry mouth, compared to the placebo groups. The authors noted that these safety findings stemmed from a small number of trials, which leaves the exact frequency of side effects uncertain.

Existing Trial Data Remains Too Weak to Form Firm Conclusions

The findings indicate that current studies lack the quality required to establish whether medical cannabis works for insomnia. Reviewers rated their confidence in the available evidence as low or very low. Dr. Lucia Varela from the University of Manitoba explained that this rating reflects limitations in study design, small sample sizes, conflicting findings, and potential trial bias rather than absolute proof that cannabis cannot help sleep.

Quality of life measurements also yielded contradictory signals. When researchers pooled the study data, quality of life estimates ranged from a slight decrease to a substantial improvement. Because of inconsistent methods across trials, the team concluded that existing research cannot answer whether medical cannabis offers dependable sleep benefits for the general population.

Established Behavioral Interventions Remain Primary Options for Recovery

Sleep plays a direct role in hormone regulation, insulin sensitivity, and physical recovery. Chronic insomnia impairs daytime metabolic functioning and increases the likelihood of mood disorders such as anxiety or depression. When sleeplessness persists, standard treatments include cognitive behavioral therapy to address habits that interfere with rest, as well as prescribed medications when indicated.

Individuals evaluating treatment options for persistent insomnia should discuss evidence-based approaches with their clinician before testing unregulated products or changing medications. While interest in cannabinoid therapies remains high, dependable guidance requires larger randomized clinical trials that follow standardized dosing protocols and validate clinical outcomes over longer observation periods.